Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1D | O15297 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL278515 | 1.00 | PPM1D (0.33) | PPM1D | |
| SCHEMBL277966 | 1.00 | PPM1D (0.33) | PPM1D | |
| SCHEMBL1896226 | 0.92 | PPM1D (0.35) | PPM1D | |
| SCHEMBL16516673 | 0.89 | PPM1D (0.33) | PPM1D | |
| SCHEMBL1015667 | 0.88 | PPM1D (0.34) | PPM1D | |
| SCHEMBL20758481 | 0.88 | PPM1D (0.34) | PPM1D | |
| SCHEMBL18535817 | 0.88 | PPM1D (0.34) | PPM1D | |
| SCHEMBL5831542 | 0.88 | PPM1D (0.34) | PPM1D | |
| SCHEMBL360950 | 0.88 | PPM1D (0.36) | PPM1D | |
| SCHEMBL661089 | 0.88 | PPM1D (0.34) | PPM1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 241 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117627305-A | Degradable stone-plastic floor and preparation method thereof | 浙江海象新材料股份有限公司 | 2024-03-01 | — | — | CN | claimed |
| EP-3623372-B1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH INC (US) | 2026-02-04 | — | — | EP | disclosed |
| EP-4665733-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | Bristol-Myers Squibb Company (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-2025235874-A1 | HETEROCYCLICS AS EGFR INHIBITORS | SCHRÖDINGER, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20250270211-A1 | COMPOUNDS FOR FGFR INHIBITION | COGENT BIOSCIENCES, INC. | 2025-08-28 | — | — | US | disclosed |
| EP-4134364-B1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2025-07-30 | — | — | EP | disclosed |
| US-20250221988-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI), INC. (CN) | 2025-07-10 | — | — | US | disclosed |
| US-12351581-B2 | Compounds for FGFR inhibition | COGENT BIOSCIENCES, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| CN-120077028-A | Thiadiazole derivative, composition and application thereof | 北京丹擎医药科技有限公司 | 2025-05-30 | — | — | CN | disclosed |
| WO-2025034912-A9 | COMPOUNDS FOR FGFR INHIBITION | COGENT BIOSCIENCES, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| US-5223620-A | For antitumor agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-06-29 | — | — | US | disclosed |
| EP-0537269-A1 | NOVEL IMMUNOSUPPRESSIVE COMPOUNDS. | VERTEX PHARMA (US) | 1993-04-21 | — | — | EP | disclosed |
| US-5192773-A | Isomerase inhibitor | VERTEX PHARMACEUTICALS, INC. (US) | 1993-03-09 | — | — | US | disclosed |
| WO-1992019593-A1 | NOVEL IMMUNOSUPPRESSIVE COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1992-11-12 | — | — | WO | disclosed |
| US-5099020-A | Immunoassay with fluorescent compounds | ABBOTT LABORATORIES (US) | 1992-03-24 | — | — | US | disclosed |
| US-5096838-A | Fluorescent tracers for detection of barbiturates and for antiserums | ABBOTT LABORATORIES (US) | 1992-03-17 | — | — | US | disclosed |
| WO-1992000278-A1 | NOVEL IMMUNOSUPPRESSIVE COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1992-01-09 | — | — | WO | disclosed |
| EP-0430065-A2 | Barbiturate assay compositions and methods | ABBOTT LABORATORIES (US) | 1991-06-05 | — | — | EP | disclosed |
| US-4946846-A | ANTITUMOR AGENTS; NONTOXIC | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-08-07 | — | — | US | disclosed |
| EP-0340905-A1 | Fused pyrimidines, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1989-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250221988-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | GSPT1, GSS, G6PC1 | PPM1D 932/4885 |
| US-20250270211-A1 | COMPOUNDS FOR FGFR INHIBITION | FGFR1, FGFR4, FGFR3 | PPM1D 1369/4885 |
| US-12351581-B2 | Compounds for FGFR inhibition | FGFR1, FGFR4, FGFR3 | PPM1D 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.